Company: JUNS
Filing Date: 2025-11-26
Form Type: S-1
Source: 0001493152-25-025204
Chunk: 165

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-11-26
Form: S-1
Chunk 165
---
 https://en.pharm.com.cn/, that
advocates the corporate core values of “Love, Integrity and Power”. TCM products are run in a separate division within Tianjin.
The Asian market is very large and hard to penetrate for a small company and we believe that our strategy with these agreements have the
possibility to accelerate an out-licensing deal in the South-East Asian territories. However, there are no assurances that this approach
will be successful.

Our rationale for the strong
approach into the South-East Asian market is:

| ● | Background: Asian countries are not accepting pharmaceutical                                           
 products to be sold without clinical trial approvals based on trials conducted in an Asian population. |

| ● | The Company’s strategy is to partner with organizations                                             
 in the territory that can execute much more efficiently than trying to manage the process from USA. |

| ● | We have already received interest for our JOTROL™                                          
 product in the Asian market since resveratrol is listed as a Traditional Chinese Medicine. |

| ● | The need for a set up that can service this market is imperative 
 for success.                                                     |

| ● | Strategic collaboration agreements have been executed to facilitate                                                               
 an expedited execution of an out-licensing agreement with one or more Chinese or other South-East Asian pharmaceutical companies. |

| ● | The Company is too small, both financially as well as internal 
 manpower, to manage developments in the territory.             |

| ● | The Company has a history of poor financial status and inability to fulfill commitments and finalize clinical 
 studies.                                                                                                      |

| ● | By utilizing equity as service payments, the company believes            
 that it can get projects finalized without any significant cash outflow. |

| ● | The service agreements are therefore designed to be a win for                                                                                  
 both parties, assuming an increase in equity value, in case clinical studies and out-licensing activities will be successful in the territory. |

Other Material Agreements

The agreement with a major
pharmaceutical company, restricted by confidentiality, grants us data access to resveratrol toxicology studies through a letter of reference.
Executed on May 2, 2017, it can only be terminated due to a material breach and there is no time limit on access to this study. The studies
were conducted at Charles River Laboratories, and there are no payments associated with this agreement.

Service Agreements - South-East Asia

On June 3, 2024, the Company
entered into three service agreements to